Research programme: immunotherapeutics - Formula Pharmaceuticals

Drug Profile

Research programme: immunotherapeutics - Formula Pharmaceuticals

Alternative Names: C.I.K.-CAR.CD19; C.I.K.-CAR.CD23; C.I.K.-CAR.CD33

Latest Information Update: 11 Aug 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator University of Milan Bicocca
  • Developer Formula Pharmaceutical
  • Class
  • Mechanism of Action Cytokine-induced killer cell replacements; IgE receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma; Solid tumours

Most Recent Events

  • 03 Aug 2015 Formula Pharmaceuticals and the Max Delbrück Center for Molecular Medicine enters into an exclusive licensing agreement and strategic collaboration to develop cytokine induced killer cell based CAR immunotherapies
  • 11 May 2015 Formula Pharmaceuticals in-licenses allogeneic, non-viral chimeric antigen receptor (CAR) technology platform from University of Milano-Bicocca
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top